Source 1primary paper2022Nature Communications
Toolkit/ECN-pE(C/A)2
ECN-pE(C/A)2
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
PubMed figure captions for the anchor paper indicate a specific construct designation, ECN-pE(C/A)2, in a study on programmable probiotics for IBD after oral delivery.
Usefulness & Problems
Why this is useful
ECN-pE(C/A)2 is presented as a named engineered probiotic construct in the anchor paper for treating inflammatory bowel disease after oral delivery. The supplied evidence links it to inflammation modulation and gut microbiota effects.; engineered probiotic treatment of inflammatory bowel disease; oral delivery of programmable probiotic therapeutics; modulating inflammation and gut microbiota
Source:
ECN-pE(C/A)2 is presented as a named engineered probiotic construct in the anchor paper for treating inflammatory bowel disease after oral delivery. The supplied evidence links it to inflammation modulation and gut microbiota effects.
Source:
engineered probiotic treatment of inflammatory bowel disease
Source:
oral delivery of programmable probiotic therapeutics
Source:
modulating inflammation and gut microbiota
Problem solved
It is intended to enable programmable probiotic therapy in the gut for inflammatory bowel disease. The paper framing suggests it addresses the challenge of combining live bacterial therapy with effective oral delivery.; combines programmable probiotic function with an orally delivered IBD treatment context
Source:
It is intended to enable programmable probiotic therapy in the gut for inflammatory bowel disease. The paper framing suggests it addresses the challenge of combining live bacterial therapy with effective oral delivery.
Source:
combines programmable probiotic function with an orally delivered IBD treatment context
Problem links
combines programmable probiotic function with an orally delivered IBD treatment context
LiteratureIt is intended to enable programmable probiotic therapy in the gut for inflammatory bowel disease. The paper framing suggests it addresses the challenge of combining live bacterial therapy with effective oral delivery.
Source:
It is intended to enable programmable probiotic therapy in the gut for inflammatory bowel disease. The paper framing suggests it addresses the challenge of combining live bacterial therapy with effective oral delivery.
Published Workflows
Objective: Develop an orally delivered programmable probiotic therapy for inflammatory bowel disease that modulates inflammation and gut microbiota.
Why it works: The supplied evidence indicates that the study combines an engineered probiotic chassis with oral delivery materials and evaluates both inflammation-related and microbiome-related endpoints in an IBD context.
reactive oxygen species-relevant enzymatic activityprobiotic engineeringoral delivery formulation
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A composed arrangement of multiple parts that instantiates one or more mechanisms.
Mechanisms
No mechanism tags yet.
Techniques
Computational DesignTarget processes
No target processes tagged yet.
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationimplementation constraint: multi component delivery burdenimplementation constraint: payload burdenoperating role: actuatorswitch architecture: multi component
The construct appears to use an Escherichia coli Nissle 1917 chassis and an oral delivery formulation. The exact genetic architecture and formulation details are not available in the provided evidence.; requires the Escherichia coli Nissle 1917 probiotic chassis according to the supplied source summary; appears tied to oral delivery materials and formulation details not fully specified in the provided text
The provided evidence does not show that this name alone specifies the full payload design, mechanism, or manufacturing workflow. It also does not establish performance boundaries versus other engineered probiotic constructs.; exact construct expansion and payload architecture are not provided in the supplied evidence
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
The anchor paper includes a named engineered probiotic construct designated ECN-pE(C/A)2.
The anchor paper uses alginate and chitosan as oral delivery materials for the programmable probiotic therapeutic context.
Approval Evidence
1 source1 linked approval claimfirst-pass slug ecn-pe-c-a-2
PubMed figure captions for the anchor paper indicate a specific construct designation, ECN-pE(C/A)2, in a study on programmable probiotics for IBD after oral delivery.
Source:
construct presencesupports
The anchor paper includes a named engineered probiotic construct designated ECN-pE(C/A)2.
Source:
Comparisons
Source-stated alternatives
The web summary points to related engineered EcN systems and other engineered probiotic IBD approaches as nearby alternatives. However, the supplied evidence does not provide a direct head-to-head comparison within this paper.
Source:
The web summary points to related engineered EcN systems and other engineered probiotic IBD approaches as nearby alternatives. However, the supplied evidence does not provide a direct head-to-head comparison within this paper.
Source-backed strengths
explicitly named engineered construct in the anchor paper
Source:
explicitly named engineered construct in the anchor paper
Compared with CAR-engineered macrophages
ECN-pE(C/A)2 and CAR-engineered macrophages address a similar problem space.
Shared frame: same top-level item type
Compared with chGFE3
ECN-pE(C/A)2 and chGFE3 address a similar problem space.
Shared frame: same top-level item type
Compared with Cry/Vip pyramiding
ECN-pE(C/A)2 and Cry/Vip pyramiding address a similar problem space.
Shared frame: same top-level item type
Ranked Citations
- 1.